
Taletrectinib is Suitable for First- and Second-Line ROS1+ NSCLC
In the wake of taletrectinib’s (Ibtrozi) approval in ROS1-positive non–small cell lung cancer (NSCLC), CancerNetwork® spoke with Jorge Nieva, MD, about how this change in the landscape might affect his practice.1 The FDA’s approval of taletrectinib was …